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Edited by Richard MaraisAbstract Interferon-a (IFN-a) is currently used for the therapy
of multiple myeloma (MM) though it is only eﬀective in some
patients. IFN-a induces apoptosis in some MM cell lines and it
has been proposed to occur through an autocrine loop involving
Apo2L/TRAIL. We have analysed the sensitivity to IFN-a and
Apo2L/TRAIL of ﬁve MM cell lines and found no correlation
between the apoptosis inducing ability of both cytokines. IFN-
a-induced apoptosis in MM cells was not prevented by a cas-
pase-8 selective inhibitor (Z-IETD-fmk) or blocking Apo2L/
TRAIL. However, human monocytes treated with IFN-a release
bioactive Apo2L/TRAIL to culture media which was cytotoxic
for MM cells resistant to IFN-a. We propose that Apo2L/
TRAIL released from IFN-a-stimulated blood monocytes would
be a major mediator of the anti-myeloma eﬀect of IFN-a in vivo.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Interferon-a (IFN-a), a cytokine originally discovered by its
anti-viral activity, is normally synthesized by macrophages and
dendritic cells and is currently used in the therapy of some
haematologic neoplasias such as hairy cell leukaemia [1] and
chronic myelogenous leukemia [2]. IFN-a has been also used
in multiple myeloma (MM) maintenance therapy for more
than 25 years, but with conﬂicting results [3]. Clinical data sug-
gest that only 5–10% of patients could really beneﬁt from IFN-
a therapy [4]. Unfortunately, there are no predictive factors
that can identify these patients. A major diﬃculty to the
rational use of IFN-a in myeloma therapy is the insuﬃcient
information available about its mechanism of cell growth
suppression. In some MM cell lines and cells from patients
IFN-a induces apoptosis [5,6], but the precise pathway in-
volved remains unclear. Recently, it has been proposed that
IFN-a-induced apoptosis in myeloma cells occurs through
the up-regulation and release of Apo2L/TRAIL in an auto-
crine fashion [5,7]. Since we were interested in the usefulness
of both cytokines for selective myeloma therapy we have*Corresponding author.
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IFN-a and Apo2L/TRAIL in a number of MM cell lines.
Our results indicate that the direct apoptotic eﬀects of IFN-a
and Apo2L/TRAIL on human MM cells occur through
essentially diﬀerent mechanisms. However, normal human
monocytes stimulated with IFN-a secrete signiﬁcant amounts
of bioactive Apo2L/TRAIL suggesting that this death ligand
is a major mediator of the IFN-a apoptotic potential in vivo.2. Materials and methods
2.1. Materials
Recombinant human interferon-a (IFN-a, speciﬁc activity
1.8 · 108 U/mg) was from PeproTechEC (London, UK), recombinant
human Apo2L/TRAIL (Apo2L/TRAIL.0) [8] and blocking anti-
Apo2L/TRAIL antibody 5C2 were from Genentech (CA, USA),
DR5- Fc (TRAILR2) chimera was from R&D Systems Vitro (Madrid,
Spain), cytotoxic antihuman Fas antibody (CH-11) was from Upstate
(NY, USA) and blocking anti-Fas antibody (SM1/23) from Bender
(Barcelona, Spain). Peptide caspase inhibitors Z-VAD-fmk and Z-
DEVD-fmk were from Bachem (Switzerland) and Z-IETD-fmk from
BD Biosciences (Madrid, Spain).
2.2. Cell proliferation and toxicity assays
Human multiple myeloma (MM) cell lines MM.1S, RPMI 8226,
NCI-H929, U266 (clone B1) and IM-9 were from the ATCC. All cells
were cultured at 37 C in RPMI 1640 medium supplemented with 10%
fetal calf serum, L-glutamine and penicillin/streptomycin (hereafter,
complete medium). Peripheral blood mononuclear cells (PBMC),
obtained as described [9], were cultured in complete medium in poly-
styrene culture ﬂasks at 37 C for 2 h to favour monocyte adhesion.
After vigorously washing with RPMI medium the remaining adherent
cells, were considered as monocytes. Monocytes (13 · 106 cells in
10 ml) or MM cells were cultured for 48 h in the presence or absence
of IFN-a (2000 U/ml) and culture supernatants used in bioassays. In
proliferation assays, MM cells (3–5 · 105 cells/ml) were treated in ﬂat-
bottom, 24-well (1 ml/well) or 96-well plates (100 ll/well) with 2000 U/
ml IFN-a, 100 ng/ml Apo2L/TRAIL or 100 ng/ml cytotoxic anti-Fas
in complete medium for diﬀerent times, as indicated. The eﬀect of
caspase inhibitors Z-DEVD-fmk, Z-IETD-fmk or ZVAD-fmk (all at
100 lM) on IFN-a and Apo2L/TRAIL toxicity was evaluated. Inhib-
itors were added 1 h prior to treatment with IFN-a or Apo2L/TRAIL.
In some experiments, cytotoxicity of Apo2L/TRAIL in culture media
was neutralized by preincubation with 100 ng/ml blocking anti-
Apo2L/TRAIL (5C2), or with 200 ng/ml of a DR5-Fc chimera, as
validated in previous studies [9].2.3. Flow cytometry analysis
Apoptosis was evaluated by the simultaneous determination of
phosphatidylserine (PS) exposure and mitochondrial membrane poten-
tial (DWm) in the same cells. Brieﬂy, cells (2.5 · 105 in 200 ll) were
incubated with 2 nM DiOC6(3) (Molecular Probes) at 37 C for
10 min in binding buﬀer (140 mM NaCl, 2.5 mM CaCl2, 10 mM
HEPES/NaOH, and pH 7.4). Then, 0.5 lg/ml annexin V-PE (Caltag)ation of European Biochemical Societies.
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pension was diluted to 1 ml with binding buﬀer and analysed in a ﬂow
cytometer (Epics XL-MCL, Beckman/Coulter). Changes in the levels
of intracellular Apo2L/TRAIL during the IFN-a treatment were eval-
uated by ﬂow cytometry. Cells (5 · 105) were cultured in complete
medium (controls) or medium containing IFN-a for diﬀerent times
(12–48 h). Then, cells were washed and ﬁxed with 1% paraformalde-
hyde in PBS (15 min, 4 C) and incubated for 1 h at 20 C with 1 lg/
ml anti-Apo2L/TRAIL (5C2, Genentech) in 50 ll PBS containing
0.1% saponin. Cells were washed with PBS and then incubated for
30 min with a FITC-labelled anti-mouse IgG antibody (Caltag),
diluted to 500 ll and analysed by ﬂow cytometry. Cell surface expres-
sion of IFN-a/b receptor was carried out by incubating cells (3 · 105)
with 2 lg/ml anti-IFNR2 antibody (MMHAR-2, Calbiochem) in
50 ll PBS and 50 ll human AB serum, at 20 C for 30 min followed
by incubation with an anti-IgG-FITC antibody and analysed by ﬂow
cytometry.2.4. Western blot analysis
Caspase activation was analysed by Western blot by using a modiﬁ-
cation of the multiple blotting assay method, as described [10]. After
the corresponding treatments cells were lysed in 50 mM Tris/HCl,
pH 7.4 buﬀer containing 0.15 mMNaCl, 10% glycerol, 1 mMNa3VO4,
10 mM Na4P2O7, 50 mM NaF, 1 mM EDTA, 10 lg/ml leupeptin,
1 mM PMSF, and 1% Triton X-100. Solubilized proteins from equal
numbers of Trypan-blue negative cells (1 · 106/lane) were resolved by
SDS–15%PAGE, transferred to nitrocellulose membranes and incu-
bated with primary antibodies diluted in TBS-T (10 mM Tris/HCl
pH 8.0, 0.12 M, NaCl, 0.1% Tween-20, and 0.05% sodium azide), con-
taining 5% skimmed milk, as described previously [11]. Primary anti-
bodies anti human proteins used were: anti-caspase-8 (clone 5F7,
Upstate), anti-procaspase- 3 (clone 19) and anti-active caspase-3
(#557035), both from BD Biosciences and anti-Bid (AF860, R&D Sys-
tems). Membranes were washed with TBS-T and incubated with
0.2 lg/ml of the corresponding phosphatase alkaline-labelled second-Fig. 1. Cytotoxicity of anti-Fas, Apo2L/TRAIL and IFN-a in myeloma cel
(100 ng/ml) for 22 h or with IFN-a (2000 U/ml) for 48 h and apoptosis det
expression of IFN-a/b receptor in myeloma cells. Cells were sequentially incu
line) or with anti-human IgG1 Ab alone (light line) and analysed by ﬂow cyary antibody (Sigma) and revealed with BCIP/NBT, as described
[11]. Control of protein loading was achieved by reprobing with anti
b-actin (1/10000) (Sigma).3. Results
3.1. Eﬀect of IFN-a and Apo2L/TRAIL on myeloma cell
proliferation
IM-9 and MM.1S cells were completely insensitive and
RPMI 8226 cells showed a slight sensitivity to IFN-a
(Fig. 1A). However, IFN-a exerted a signiﬁcant apoptotic
eﬀect on U266 cells and NCI-H929 (around 30%). Analysis
of surface IFN-a/b receptor expression by ﬂow cytometry
revealed that the low or no expression of IFN-a/b receptor
in MM.1S and RPMI 8226 cells, respectively (Fig. 1B), could
account for the reduced sensitivity of these cells to IFN-a.
However, IM-9 cells, although refractory to IFN-a, express
signiﬁcant levels of IFN-a/b receptor (Fig. 1B). We also ana-
lysed the sensitivity of these cell lines to anti-Fas and to
Apo2L/TRAIL. RPMI 8226 cells were the more sensitive to
apoptotic eﬀects of anti-Fas and Apo2L/TRAIL (DL50: 2 ng/
ml). U266 and IM-9 cells were resistant to Apo2L/TRAIL,
but partially sensitive to anti-Fas (around 15% and 40%
speciﬁc cell death, respectively). MM.1S showed a moderate
susceptibility to both anti-Fas and Apo2L/TRAIL (18% and
34% apoptotic cells, respectively). Finally, H929 cells were sen-
sitive to Apo2L/TRAIL and resistant to anti- Fas. In general,
no correlation between the sensitivity to IFN-a and Apo2L/
TRAIL was observed among MM cell lines.ls. (A) Cells were incubated with anti-Fas (100 ng/ml), Apo2L/TRAIL
ermined by annexin-PE binding and ﬂow cytometry. (B) Cell surface
bated with an anti-IFNR2 antibody and an anti-IgG1-FITC Ab (dark
tometry.
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IFN-a and Apo2L/TRAIL on the MM cell lines. Cells were
treated for 22 h with Apo2L/TRAIL after a 48 h preincubation
with IFN-a. IFN-a did not alter the sensitivity to Apo2L/
TRAIL of most MM cell lines. In the case of H929 cells,
IFN-a pre-treatment even reduced the toxicity of Apo2L/
TRAIL (Fig. 2).
3.2. IFN-a induces release of Apo2L/TRAIL from normal
monocytes but not from MM cells
No expression of Apo2L/TRAIL in plasma membrane was
detected in any MM cell line, either in basal conditions or after
IFN-a treatment (data not shown). However, MM cells ex-
pressed detectable amounts of intracellular Apo2L/TRAIL,CONTROL
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Fig. 2. Apoptosis induction in MM cell lines by sequential treatment
with IFN-a and Apo2L/TRAIL. Cells (5 · 105 cells/ml) were cultured
for 48 h in 24-well plates in the absence or presence of 2000 U/ml IFN-
a. Then, 100 ng/ml Apo2L/TRAIL were added in some wells and cells
incubated for a further 22 h. Apoptosis was determined by measuring
annexin-PE binding by ﬂow cytometry.
Fig. 3. Eﬀect of IFN-a treatment on intracellular Apo2L/TRAIL levels. U26
indicated, permeabilised and immunostained for Apo2/TRAIL, and analysewhich transiently increased upon IFN-a treatment
(Fig. 3A,B). No release of bioactive Apo2L/TRAIL to culture
media could be detected in supernatants of IFN-a treated
U266 or H929 cells with a sensitive bioassay [9] using RPMI
8226 cells as targets (data not shown). Also, no cell death
above basal levels could be noticed in co-cultures of U266
and RPMI 8226 cells (not shown). Anyway, to rule out the
possibility that the apoptotic eﬀect of IFN-a in H929 cells
(the only sensitive both to IFN-a and Apo2L/TRAIL) could
be indirectly mediated by an autocrine loop involving
Apo2L/TRAIL, H929 cells were co-incubated with IFN-a
and with blocking anti- Apo2L/TRAIL antibodies (5C2) or
with a DR5-Fc chimera. No reduction in IFN-a toxicity was
observed in any case (Fig. 4A). However, normal human
monocytes incubated with IFN-a under comparable condi-
tions release to culture media bioactive Apo2L/TRAIL
(Fig. 4B). Conditioned media from IFN-a treated monocytes
was cytotoxic for RPMI 8226 (highly sensitive to TRAIL,
insensitive to IFN-a) and to a much lesser extent for H929 cells
(Fig. 4B). This conditioned media was not cytotoxic for U266
cells (resistant to Apo2L/TRAIL). Cytotoxicity was prevented
by co-incubation with the blocking anti-Apo2L/TRAIL anti-
body 5C2, but not by the blocking anti-Fas mAb SM1/23
(Fig. 4B). These results indicate that IFN-a induces the release
of Apo2L/TRAIL from monocytes, which in turn may cause
apoptosis in myeloma cells.
3.3. Caspase activation induced by IFN-a or Apo2L/TRAIL.
Caspase 8 or 3 inhibitors (Z-IETD-fmk and Z-DEVD-fmk,
respectively) or the pancaspase inhibitor Z-VAD-fmk fully
prevented DWm loss, PS exposure and apoptosis induced by
Apo2L/TRAIL in MM sensitive cells (Fig. 5A), according to
the key role of these caspases in the extrinsic pathway. How-
ever, these inhibitors only have a partial or no protective eﬀect
on DWm loss, PS exposure and apoptosis induced by IFN-a
(Fig. 5B). Replenishment of peptide caspase inhibitors each6 (A) and H929 (B) cells were treated with IFN-a for diﬀerent times, as
d by ﬂow cytometry.
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Fig. 4. Eﬀect of neutralizing anti-TRAIL antibodies on IFN-a toxicity. (A) Toxicity of IFN-a (2000 U/ml) to H929 cells was analysed in the absence
or presence of a blocking anti-TRAIL antibody (5C2) or a DR5-Fc chimera. After 48 h treatment, apoptosis was evaluated by annexin V-PE binding
and ﬂow cytometry. (B) Release of Apo2L/TRAIL by IFN-a treated human monocytes. Toxicity of culture supernatants of monocytes treated with
IFN-a was bioassayed by using several myeloma cells as targets. Toxicity of the supernatants was analysed in the absence or presence of blocking
anti-Apo2L/TRAIL (5C2) or anti-Fas (SM1/23) antibodies.
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Congruent with these results, caspase-8 and caspase-3, a sub-
strate of caspase-8 in the death receptor pathway, became acti-
vated in sensitive H929 cells incubated with Apo2L/TRAIL.
Caspase activation was characterized by a decrease in the
amount of proenzyme and, in the case of caspase-3, the
appearance of activation bands (Fig. 6). A reduction in the lev-
els of Bid, a speciﬁc substrate of caspase-8, was also observed
in Apo2L/TRAIL treated cells. However, no signiﬁcant reduc-
tion in the levels of caspase-8, caspase-3 and Bid was detected
in IFN-a treated cells (Fig. 6).4. Discussion
IFN-a is used in maintenance therapy in patients with multi-
ple myeloma, but its beneﬁt is still a matter of controversy [3].
IFN-a can induce apoptosis in some MM cells [5], although
most information relies in studies carried out with the U266
cell line. It has been reported that IFN-a induced apoptosis
in this cell line is accompanied by caspase activation, DWm loss,
release of cytochrome c [12] and Bak conformational change
[13]. It has been also proposed that IFN-a induces apoptosis
in myeloma cells by upregulating Apo2L/TRAIL expression
[5]. However, the precise subcellular localization of Apo2L/
TRAIL and its possible release was not analysed. In a recent
work, and using diﬀerent myeloma cell lines, it has been re-
ported that IFN-a induces upregulation of PML gene expres-
sion and this correlated with Apo2L/TRAIL induction and
release to culture media [7]. However, a measurement of the
apoptosis directly induced by IFN-a and the released
Apo2L/TRAIL on MM cell lines was not performed. Herewe show that IFN-a and Apo2L/TRAIL cause diﬀerent eﬀects
on myeloma cells and in particular they induce apoptosis
through essentially diﬀerent mechanisms. U266 cells, the most
sensitive to apoptotic eﬀects of IFN-a were insensitive to
Apo2L/TRAIL and to cytotoxic anti-Fas antibodies.
Moreover, U266 treated with IFN-a for two days were not
sensitized to Apo2L/TRAIL. Conversely, culture supernatants
of U266 cells treated with IFN-a were not cytotoxic in bioas-
says on Jurkat and RPMI 8226, which are very sensitive to the
apoptotic eﬀects of FasL and Apo2L/TRAIL, respectively ([9]
and this work). The intracellular apoptotic pathways elicited
by IFN-a and Apo2L/TRAIL were also diﬀerent since
Z-IETD-fmk (an inhibitor of caspase-8) eﬃciently blocked
apoptosis induced by Apo2L/TRAIL but not that induced
by IFN-a. A previous work [5] indicated that a stable trans-
formant, obtained after extensive selection and cloning,
expressing a dominant-negative DR5 receptor was insensitive
to both Apo2L/TRAIL and IFNa/b. However, our results
using a DR5-Fc chimera indicate that this protein blocks
apoptosis induced by Apo2L/TRAIL but not that induced
by IFN-a (Fig. 4A). Since the expression of IFN receptor in
the transformant was not assayed, the possibility that resis-
tance to IFN could be due to reduced IFNR expression cannot
be ruled out.
Therefore, IFN-a and Apo2L/TRAIL induce apoptosis
through essentially independent mechanisms in myeloma cells
and, in particular, Apo2L/TRAIL is not the direct mediator of
the cytotoxic eﬀects of IFN-a. However, these results do not
exclude Apo2L/TRAIL as a relevant mediator of IFN-a anti-
tumor eﬀect in vivo. It has been reported that host CD4+ T
and NK cells, neutrophils, and mainly monocytes increase
gene expression and/or release of Apo2L/TRAIL upon IFN-
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Fig. 5. Eﬀect of caspase inhibitors on IFN-a and Apo2L/TRAIL-induced apoptosis. Toxicity of Apo2L/TRAIL on H929 cells (A) and IFN-a on
U266 and NCI-H929 cells (B) was evaluated in the presence of Z-DEVD-fmk, Z-IETD-fmk or Z-VAD-fmk (all at 100 lM). Inhibitors were added
1 h prior to treatment with IFN-a (48 h) or Apo2L/TRAIL (22 h). PS exposure and loss of DWm were analysed by ﬂow cytometry.
Fig. 6. Distinct pattern of caspase-8 and caspase-3 activation after IFN-a or Apo2L/TRAIL treatment. H929 cells were treated with IFN-a (2000 U/
ml, 48 h) or Apo2L/TRAIL (100 ng/ml, 22 h) and caspase activation and Bid levels analysed by Western blotting with speciﬁc antibodies for
procaspase-8, procaspase-3, active caspase-3 (17 kDa band) and Bid. b-Actin levels serve as control for equal protein loading.
M. Go´mez-Benito et al. / FEBS Letters 579 (2005) 6217–6222 6221a/b treatment [14–19]. According to this, our present results
show that stimulation of monocytes with IFN-a induces the
secretion of signiﬁcant amounts of bioactive Apo2L/TRAIL,which causes apoptosis in MM cells, even in some that are
insensitive to IFN-a. Therefore, this eﬀect would be more
important in vivo than the moderate apoptotic eﬀect directly
6222 M. Go´mez-Benito et al. / FEBS Letters 579 (2005) 6217–6222exerted by IFN-a on MM cell lines. If this was the case, then
Apo2L/TRAIL would be a good candidate to replace IFN-a in
maintenance/consolidation therapy in multiple myeloma pa-
tients.
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